标题：Research Grade Dupilumab度匹鲁单抗,AntibodySystem Laboratories
链接：https://www.antibodysystem.com/product/6158.html
名称：Research Grade Dupilumab度匹鲁单抗
别名：Dupilumab度匹鲁单抗，CD124, REGN668, SAR231893
CAS: 1190264-60-8
货号：DHD62601
适用物种：Human
寄主物种：Homo sapiens
形式：Liquid
纯度：>95%
克隆性：Monoclonal
同种型：IgG4-kappa
应用：Research Grade Biosimilar
UniProt：P24394
靶点：IL-4RA, IL-4-binding protein, IL-4 receptor subunit alpha, Soluble IL-4R-alpha, IL4-BP, IL4R, IL-4R subunit alpha, IL-4R-alpha, CD124, Interleukin-4 receptor subunit alpha, IL4RA, Soluble IL-4 receptor subunit alpha, sIL4Ralpha/prot
用途范围：仅用于科研
储存：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
免费热线：027-65279366 /18108604356
QQ：2663991332
咨询邮箱：products@biolabreagent.com
选购商城：https://www.antibodysystem.com
微信公众平台：佰乐博生物Biolab Reagents
参考文献：
Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis. PMID: 36546624
Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management. PMID: 35703018
Dupilumab for treatment of atopic dermatitis. PMID: 29557246
Dupilumab-Associated Psoriasis and Psoriasiform Manifestations: A Scoping Review. PMID: 37100035
Dupilumab Facial Redness/Dupilumab Facial Dermatitis: A Guide for Clinicians. PMID: 34855151
Dupilumab: A Review of Present Indications and Off-Label Uses. PMID: 33661102
Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. PMID: 25006719
Management of inadequate response and adverse effects to dupilumab in atopic dermatitis. PMID: 34126094
Dupilumab-Associated Adverse Events During Treatment of Allergic Diseases. PMID: 35275334
Dupilumab in the treatment of genodermatosis: A systematic review. PMID: 36657040
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. PMID: 28478972
Dupilumab in Inflammatory Skin Diseases: A Systematic Review. PMID: 37189381
Dupilumab in pediatric dermatology. PMID: 32602761
Dupilumab: A review of its use in the treatment of atopic dermatitis. PMID: 29471919
Cutaneous T-cell lymphoma following dupilumab use: a systematic review. PMID: 36073768
Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. PMID: 30194992
Dupilumab ocular side effects in patients with atopic dermatitis: a systematic review. PMID: 35122335
Conjunctivitis in dupilumab clinical trials. PMID: 30851191
Treatment With Dupilumab in Patients With Atopic Dermatitis: Systematic Review and Meta-Analysis. PMID: 36214355
Phase 2a randomized clinical trial of dupilumab (anti-IL-4Ralpha) for alopecia areata patients. PMID: 34460948
Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis. PMID: 35636689
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. PMID: 32574587
Dupilumab for Atopic Dermatitis-From Clinical Trials to Molecular and Cellular Mechanisms. PMID: 36705657
Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review. PMID: 35769474
Dupilumab in the treatment of asthma. PMID: 31218914
Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma. PMID: 31521831
Dupilumab in persistent asthma with elevated eosinophil levels. PMID: 23688323
Dupilumab for atopic dermatitis. PMID: 29545264
Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up). PMID: 37230366
Dupilumab significantly improves skin barrier function in patients with moderate-to-severe atopic dermatitis. PMID: 35815904
Dupilumab Improves Clinical Scores in Children and Adolescents With Moderate to Severe Atopic Dermatitis: A Real-World, Single-Center Study. PMID: 35753667
Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid. PMID: 34721404
Dupilumab for the treatment of prurigo nodularis: A systematic review. PMID: 36742321
Dupilumab for the treatment of asthma. PMID: 28085503
Olfactory Outcomes With Dupilumab in Chronic Rhinosinusitis With Nasal Polyps. PMID: 34628065
Dupilumab in chronic rhinosinusitis with nasal polyposis: current status, challenges, and future perspectives. PMID: 37378551
The impact of dupilumab on skin barrier function: A systematic review. PMID: 36995919
Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-to-Severe Asthma. PMID: 36535524
Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND). PMID: 35439608
Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial. PMID: 31876900
Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. PMID: 35503163
Which Is the Best Biologic for Nasal Polyps: Dupilumab, Omalizumab, or Mepolizumab? A Network Meta-Analysis. PMID: 34607329
Dupilumab: First Global Approval. PMID: 28547386
Use of Dupilumab in Glucocorticoid-Dependent Asthma. PMID: 35922047
Dupilumab for the treatment of adolescents with atopic dermatitis. PMID: 32720530
Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE). PMID: 35567671
Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. PMID: 25482871
Dupilumab-associated mycosis fungoides: a cross-sectional study. PMID: 37270763
